文献速递胸部肿瘤

国际肺癌研究协会提出的第九版TNM分期系统N描述符的验证研究

Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2024-04-16

本研究在2004年1月至2019年12月间接受治愈性手术的6649例非小细胞肺癌患者中,回顾性验证新提出的第九版TNM分期N描述符的判别能力和临床效用。中位随访54个月,按新N分类重新分类后,相邻临床和病理N类别在总生存期和无复发生存期上均显示高度显著的预后差异。结论认为新N分类在临床和病理分期中均具有临床效用,各N类别间预后分离清晰。

要点

  • 新第九版N分类将临床N0、N1、N2a、N2b分别归入5573例(83.8%)、639例(9.6%)、268例(4.0%)、169例(2.5%)。
  • 病理N0、N1、N2a、N2b分别归入4957例(74.6%)、744例(11.2%)、567例(8.5%)、381例(5.7%)。
  • 所有相邻临床和病理N类别在总生存期和无复发生存期上均显示高度显著的预后差异。

核心结论

  • 新提出的第九版N分类在非小细胞肺癌的临床和病理分期中均具有临床效用,各N类别(N0、N1、N2a、N2b)在总生存期和无复发生存期上均显示清晰的预后分离。

研究设计与样本

  • 回顾性分析2004年1月至2019年12月期间接受治愈性手术的非小细胞肺癌患者,基于第九版TNM分类对N描述符进行回顾性重新分类,采用对数秩检验和Cox比例风险模型比较相邻N类别。

主要发现

  • 共纳入6649例患者,中位随访54个月。
  • 临床N0、N1、N2a、N2b分别为5573例(83.8%)、639例(9.6%)、268例(4.0%)、169例(2.5%)。
  • 病理N0、N1、N2a、N2b分别为4957例(74.6%)、744例(11.2%)、567例(8.5%)、381例(5.7%)。
  • 所有相邻临床和病理N类别在总生存期和无复发生存期上均显示高度显著的预后差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to validate the discriminatory ability and clinical utility of the N descriptor of the newly proposed ninth edition of the TNM staging system for lung cancer in a large independent cohort. METHODS: We retrospectively analyzed patients who underwent curative surgery for NSCLC between January 2004 and December 2019. The N descriptor of patients included in this study was retrospectively reclassified based on the ninth edition of the TNM classification. Survival analysis was performed using the log-rank test and Cox proportional hazard model to compare adjacent N categories. RESULTS: A total of 6649 patients were included in this study. The median follow-up period was 54 months. According to the newly proposed ninth edition N classification, 5573 patients (83.8%), 639 patients (9.6%), 268 patients (4.0%), and 169 patients (2.5%) were classified into the clinical N0, N1, N2a, and N2b categories and 4957 patients (74.6%), 744 patients (11.2%), 567 patients (8.5%), and 381 patients (5.7%) were classified into the pathologic N0, N1, N2a, and N2b categories, respectively. The prognostic differences between all adjacent clinical and pathologic N categories were highly significant in terms of both overall survival and recurrence-free survival. CONCLUSIONS: We validated the clinical utility of the newly proposed ninth edition N classification for both clinical and pathologic stages in NSCLC. The new N classification revealed clear prognostic separation between all categories (N0, N1, N2a, and N2b) in terms of both overall survival and recurrence-free survival.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kim IH, Lee GD, Choi S, et al. Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024. PMID: 38614456. doi:10.1016/j.jtho.2024.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。